SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is trending as traders closely monitor high volatility and a sharp pullback, with the community actively debating whether recent price swings are driven by index rebalancing or underlying fundamental concerns about AI power infrastructure demand. Discussions are polarized between investors viewing the drop as a compelling buying opportunity for a critical grid-stabilization play and skeptics questioning its elevated valuation and future growth scalability.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing increased volatility and social buzz as investors speculate on the upcoming Goliath mainnet launch and look for signs of institutional adoption. While some community members remain bullish on long-term infrastructure potential and accumulation patterns, others are actively warning of potential liquidity traps and past patterns of price volatility.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

Biotech is experiencing a sharp rotation of capital as investors pivot away from tech and AI, fueling significant momentum for the sector. Community sentiment is mixed between bullish enthusiasm over potential M&A activity and breakthrough trial data, and concerns regarding heightened volatility in clinical-stage companies.

What makes MOG an absolute game-changer is our relentless dedication to memes and viral brilliance! We don't settle for mediocrity; we plunge into the realm of sheer awesomeness! Our community is a powerhouse of meme warriors, unleashing an unstoppable onslaught of viral memes that'll leave you in awe and stitches!  We're not here to play games; we're here to dominate! MOG is all about pushing the boundaries, smashing through barriers, and leaving our competitors eating our dust! Our passion for humor burns like an inferno, and we won't rest until the entire internet bows down to our meme supremacy!  And our community? It's a brotherhood, an unyielding powerhouse of support and camaraderie! When you're part of MOG, you're part of an unstoppable force, a family forged by the fire of meme revolution!  So, if you're ready to be part of the most intense, mind-bending memecoin movement ever conceived, then buckle up, strap in, and brace yourself! MOG is here to claim the throne, and we're taking no prisoners! Get ready to witness meme history in the making!

 MOG Coin

MOG Coin is currently trending amidst a highly polarized community debate, with some traders actively looking for bullish reversals and potential 10x gains, while a vocal contingent of investors dismisses the asset as a scam or a failing pump-and-dump scheme. Discussion is further fueled by speculative chatter regarding potential future ETF applications and broader meme coin sector trends, leading to sharp disagreements over the coin's long-term viability versus its perceived lack of utility.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immix Biopharma is trending due to heightened institutional accumulation and excitement surrounding the company's progress with NXC-201, as index funds and major firms continue to build positions ahead of key milestones and potential regulatory catalysts. Community members are closely tracking trial enrollment updates and regulatory pathways, with many viewing the company as a prime candidate for strategic acquisition due to its disruptive CAR-T technology.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

Occidental Petroleum is capturing significant investor attention as market participants navigate extreme volatility driven by persistent geopolitical tensions in the Strait of Hormuz and contradictory reports surrounding potential ceasefire negotiations. The community remains deeply divided, with many traders analyzing the company's strong FCF potential and debt-reduction progress while others caution against the impact of macro-driven price swings and the risks associated with betting on sensitive energy-sector headlines.

Charter Communications, Inc. engages in providing broadband communications services. Its services include Spectrum TV, Spectrum Internet, and Spectrum Voice. It offers business-to-business Internet access, data networking, business telephone, video and music entertainment services, and wireless backhaul. Its advertising sales division, Spectrum Reach, offers local, regional, and national businesses the opportunity to advertise in individual and multiple service areas on cable television networks and advanced advertising platforms. The company was founded in 1993 and is headquartered in Stamford, CT.

Charter Communications Inc. - Ordinary Shares - Class A

Charter Communications is currently experiencing heightened volatility and intense short-seller activity as investors react to the company's removal from the NASDAQ-100 and ongoing concerns regarding debt levels and broadband subscriber churn. Community discourse is sharply divided between retail traders debating the stock's long-term value and deep-value potential, and aggressive bears capitalizing on the stock's downward trend.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is seeing increased market attention driven by positive clinical data and high levels of institutional ownership, leading to community debate over potential M&A activity and management's effectiveness. Traders are closely monitoring key technical levels and unusual options activity as participants weigh the company's growth outlook against lingering frustration over historical price volatility.

ProShares Trust - ProShares Bitcoin ETF

ProShares Bitcoin Strategy ETF

BITO is facing heavy downward pressure as Bitcoin experiences a sharp liquidity flush, leading investors to debate whether the current price represents a buying opportunity for long-term holders or a trap amid continued price decay. Community sentiment is deeply split between those aggressively averaging down to capitalize on the monthly dividend yield and those divesting due to frustration over eroding share value and the volatility of the underlying futures market.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X ETF

Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bear 3X Shares (LABD) is trending as traders closely monitor the record-breaking volatility and persistent divergence in the underlying XBI index, which continues to hit new highs despite significant geopolitical and macroeconomic headwinds. The community is actively debating the sustainability of this rally, with many traders using LABD for tactical swings while expressing frustration over the ETF's aggressive decay and its recurring failure to capture sustained downward momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher

PDS Biotechnology (PDSB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript

PDS Biotechnology Corporation (NASDAQ:PDSB) Short Interest Down 16.3% in April

PDS Biotechnology Corporation (NASDAQ:PDSB - Get Free Report) was the recipient of a significant decrease in short interest during the month of April. As of April 15th, there was short interest...

PDS Biotechnology (NASDAQ:PDSB) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of PDS Biotechnology in a research note on Wednesday...

Why Is PDS Biotechnology Stock Gaining Wednesday?

PDS Biotechnology says Phase 2 data show higher response rates and survival trends in colorectal cancer and prostate cancer studies.read more...

PDSB Stock Hits 37-Week High — Here’s The Latest On Its Therapy To Treat Metastatic Colorectal Cancer

Equity

The biotech firm said its Phase 2 trial of PDS01ADC showed a strong objective response rate and a 24-month survival rate.

PDS Biotechnology (PDSB) Upgraded to Buy: Here's Why

PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PDS Biotechnology Stock Logs Best Session In 2 Months After FDA Fast-Track Push For Cancer Drug — Retail Bets On Early Approval

Align Technology Stock Surges After-Hours On Teen Demand — Retail Sees Rally Ahead Into 2026

Take the Zacks Approach to Beat the Markets: StoneCo, Axon, Intuit in Focus

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products include PDS0101 and PDS01ADC. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.

PDS Biotechnology Corporation

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

PDSBPDS Biotechnology Corporation

Fundamentals

Latest PDSB News